Dr. Shaw on the Phase III Results of the ALEX Trial in NSCLC

Alice T. Shaw, MD, PhD
Published: Monday, Jun 05, 2017



Alice T. Shaw, MD, PhD, associate professor of medicine, Harvard Medical School, attending physician, Thoracic Cancer Program, Massachusetts General Hospital, discusses the phase III results of the international ALEX trial, which compared the alectinib (Alecensa) with crizotinib (Xalkori) in the frontline setting for patients with ALK-positive, metastatic non–small cell lung cancer (NSCLC).

<<< View more from the 2017 ASCO Annual Meeting


Alice T. Shaw, MD, PhD, associate professor of medicine, Harvard Medical School, attending physician, Thoracic Cancer Program, Massachusetts General Hospital, discusses the phase III results of the international ALEX trial, which compared the alectinib (Alecensa) with crizotinib (Xalkori) in the frontline setting for patients with ALK-positive, metastatic non–small cell lung cancer (NSCLC).

<<< View more from the 2017 ASCO Annual Meeting

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x